← Theranostic Atlas Therapy radar Imaging radar All targets Molecules Français Molecules
Pentetreotide Target SSTR 2/3 Class Peptide (somatostatin analogue, DTPA chelator) Other names DTPA-octreotide
0 ongoing trials
1 radiolabelled forms
1 approved products
979 publications (PubMed)
Structure 3D 2D
Structure from the cited PubChem record (unlabelled ligand, or the labelled form when PubChem only describes that one). Conformer: RDKit (computed conformer, indicative). Rotate with the mouse or a finger.
Properties (PubChem) Molecular formula C63H87N13O19S2 Molar mass (g/mol) 1,394.6 Exact mass (Da) 1,393.5683 XLogP -9.4 H-bond donors 17 H-bond acceptors 25 Rotatable bonds 34 Heavy atoms 97 InChIKey CNLWNYCFDMAZCB-HUVROIHYSA-N PubChem record CID 72128 ↗ IUPAC name 2-[2-[[2-[[(2R)-1-[[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-16-benzyl-4-[[(2R,3R)-1,3-dihydroxybutan-2-yl]carbamoyl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]-(carboxymethyl)amino]ethyl-[2-[bis(carboxymethyl)amino]ethyl]amino]acetic acid SMILES C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)[C@@H](CC5=CC=CC=C5)NC(=O)CN(CCN(CCN(CC(=O)O)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)N[C@H](CO)[C@@H](C)O)O Radiolabelled forms Form Use Molar mass (labelled form) Ongoing trials Most advanced phase Approval [¹¹¹In]In-pentetreotide Syntheses and QC ↗ Imaging 1,472.4 0 — Octreoscan US EU FR JP
979 publications in PubMed for the query below; the most recent:
pentetreotide[tiab] OR Octreoscan[tiab]
Characterizing bone metastases and skeletal-related events in patients with well-differentiated neuroendocrine neoplasms utilizing (68)Gallium-DOTATATE positron emission tomography J Neuroendocrinol, 2026 The Use and Utility of Preoperative Somatostatin Receptor-Based Imaging in Gastroenteropancreatic Neuroendocrine Tumors Ann Surg Oncol, 2026 The indolent nature of gastroblastoma. Report of an illustrative case with 28 years of follow-up showing previously unreported immunohistochemical and molecular features Virchows Arch, 2026 Three Cases of Merkel Cell Carcinoma Treated With Lutetium-177 Oxodotreotide J Dermatol, 2026 Feasibility of treating neuroendocrine prostate cancer with anti-SSTR radioligands: A systematic review of imaging and treatment studies Semin Nucl Med, 2026 Solitary left frontotemporal neuroendocrine metastasis mimicking a high-grade astrocytoma Surg Neurol Int, 2026 Shifts in Urbanicity-Based Access to Radiotracers for Neuroendocrine Tumors J Am Coll Radiol, 2026 Somatostatin receptor expression for peptide receptor radionuclide therapy in Japanese patients with recurrent or metastatic differentiated thyroid cancer Ann Nucl Med, 2026 Sources: PubChem and PubMed (NCBI), ClinicalTrials.gov and CTIS registries, approvals recorded by the atlas. PubChem data as of 28 October 2026.
Cite this page Pentetreotide. Theranostic Atlas, LaRadiopharmacie.fr. Data as of 27 October 2026. https://theranosticatlas.com/molecule/pentetreotide/ (accessed [date]).
A monitoring tool with no regulatory value: check every item at its source.